Wide Ranks

GTBP

GT Biopharma, Inc.

2.86

Top Statistics
Market Cap 6 M Forward PE -0.2648 Revenue Growth 0.00 %
Current Ratio 2.46 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 9 M Total Cash Per Share 4.14 Total Debt
Total Debt To Equity Current Ratio 2.46 Book Value Per Share 5.41
All Measures
Short Ratio 71.00 % Message Board Id finmb_265434 Shares Short Prior Month 5017
Return On Equity -1.31 City Brisbane Uuid 88fa099a-560e-3a9f-8e72-6f076873cda8
Previous Close 3.04 First Trade Date Epoch Utc 1 B Book Value 5.41
Beta 0.5700 Volume 6952 Price To Book 0.5283
Last Split Date 1 B Fifty Two Week Low 1.92 Total Cash Per Share 4.14
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -11354000 Short Percent Of Float 0.0081 Implied Shares Outstanding 2 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 19240
Average Volume10days 19240 Total Cash 9 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1215 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 3.04 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.61 Open 2.97
Free Cashflow -8036375 State CA Dividend Yield 0.00 %
Return On Assets -0.6059 Time Zone Short Name EST Trailing Eps -7.39
Day Low 2.86 Address1 8000 Marina Boulevard Shares Outstanding 2 M
Price Hint 4 Target High Price 0.0000 Website https://www.gtbiopharma.com
52 Week Change -0.5667 Average Volume 18745 Forward Eps -10.80
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 246.00 %
Last Split Factor 1:30 Regular Market Day High 3.01 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 10.66 Day High 3.01
Shares Short 17725 Regular Market Open 2.97 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0079
Operating Cashflow -11710000 Currency USD Time Zone Full Name America/New_York
Market Cap 6 M Is_nasdaq_100 False Zip 94005
Quote Type EQUITY Industry Biotechnology Long Name GT Biopharma, Inc.
Regular Market Day Low 2.86 Held Percent Institutions 0.6752 Current Price 2.86
Address2 Suite 100 Financial Currency USD Current Ratio 2.46
Industry Disp Biotechnology Country United States Float Shares 1 M
Two Hundred Day Average 3.13 Ir Website http://oxis.investorroom.com/ Enterprise Value -2723762
Forward PE -0.2648 Regular Market Volume 6952 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.

The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.

The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.

GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.